MicroRNAs Located in the Hox Gene Clusters Are Implicated in Huntington's Disease Pathogenesis

Transcriptional dysregulation has long been recognized as central to the pathogenesis of Huntington's disease (HD). MicroRNAs (miRNAs) represent a major system of post-transcriptional regulation, by either preventing translational initiation or by targeting transcripts for storage or for degradation. Using next-generation miRNA sequencing in prefrontal cortex (Brodmann Area 9) of twelve HD and nine controls, we identified five miRNAs (miR-10b-5p, miR-196a-5p, miR-196b-5p, miR-615-3p and miR-1247-5p) up-regulated in HD at genome-wide significance (FDR q-value<0.05). Three of these, miR-196a-5p, miR-196b-5p and miR-615-3p, were expressed at near zero levels in control brains. Expression was verified for all five miRNAs using reverse transcription quantitative PCR and all but miR-1247-5p were replicated in an independent sample (8HD/8C). Ectopic miR-10b-5p expression in PC12 HTT-Q73 cells increased survival by MTT assay and cell viability staining suggesting increased expression may be a protective response. All of the miRNAs but miR-1247-5p are located in intergenic regions of Hox clusters. Total mRNA sequencing in the same samples identified fifteen of 55 genes within the Hox cluster gene regions as differentially expressed in HD, and the Hox genes immediately adjacent to the four Hox cluster miRNAs as up-regulated. Pathway analysis of mRNA targets of these miRNAs implicated functions for neuronal differentiation, neurite outgrowth, cell death and survival. In regression models among the HD brains, huntingtin CAG repeat size, onset age and age at death were independently found to be inversely related to miR-10b-5p levels. CAG repeat size and onset age were independently inversely related to miR-196a-5p, onset age was inversely related to miR-196b-5p and age at death was inversely related to miR-615-3p expression. These results suggest these Hox-related miRNAs may be involved in neuroprotective response in HD. Recently, miRNAs have shown promise as biomarkers for human diseases and given their relationship to disease expression, these miRNAs are biomarker candidates in HD.

[1]  Yu-Fan Chang,et al.  miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models. , 2013, American journal of human genetics.

[2]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[3]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[4]  Elena Cattaneo,et al.  A microRNA-based gene dysregulation pathway in Huntington's disease , 2008, Neurobiology of Disease.

[5]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[6]  D. Rubinsztein,et al.  Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. , 2001, Human molecular genetics.

[7]  L. Stanton,et al.  Dysregulation of REST‐regulated coding and non‐coding RNAs in a cellular model of Huntington's disease , 2013, Journal of neurochemistry.

[8]  M. Sinha,et al.  Micro RNA -214,-150,-146a and-125b target Huntingtin gene , 2011, RNA biology.

[9]  Sandrine Humbert.  Is Huntington disease a developmental disorder? , 2010, EMBO reports.

[10]  A. Dale,et al.  Regional and progressive thinning of the cortical ribbon in Huntington’s disease , 2002, Neurology.

[11]  T. Lufkin,et al.  Nuclear Accumulation of an Uncapped RNA Produced by Drosha Cleavage of a Transcript Encoding miR-10b and HOXD4 , 2011, PloS one.

[12]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[13]  Katalin Illes,et al.  Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. , 2006, Human molecular genetics.

[14]  Gregory J. Hannon,et al.  MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies , 2005, Nature Cell Biology.

[15]  H. Allgayer,et al.  MicroRNAs-10a and -10b Contribute to Retinoic Acid-induced Differentiation of Neuroblastoma Cells and Target the Alternative Splicing Regulatory Factor SFRS1 (SF2/ASF)* , 2010, The Journal of Biological Chemistry.

[16]  M. Kiebler,et al.  Dynamic Interaction between P-Bodies and Transport Ribonucleoprotein Particles in Dendrites of Mature Hippocampal Neurons , 2008, The Journal of Neuroscience.

[17]  Harsh Dweep,et al.  Parallel Analysis of mRNA and microRNA Microarray Profiles to Explore Functional Regulatory Patterns in Polycystic Kidney Disease: Using PKD/Mhm Rat Model , 2013, PloS one.

[18]  J. Cha,et al.  Transcriptional dysregulation in Huntington’s disease , 2000, Trends in Neurosciences.

[19]  M. Lerch,et al.  Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer. , 2009, Gastroenterology.

[20]  I. Módy,et al.  Pathological Cell-Cell Interactions Elicited by a Neuropathogenic Form of Mutant Huntingtin Contribute to Cortical Pathogenesis in HD Mice , 2005, Neuron.

[21]  Laurent Gil,et al.  Ensembl 2013 , 2012, Nucleic Acids Res..

[22]  Arek Kasprzyk,et al.  BioMart: driving a paradigm change in biological data management , 2011, Database J. Biol. Databases Curation.

[23]  Jung-Eun Park,et al.  Altered microRNA regulation in Huntington's disease models , 2011, Experimental Neurology.

[24]  D. Rubinsztein,et al.  Modulation of polyglutamine-induced cell death by genes identified by expression profiling. , 2002, Human molecular genetics.

[25]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[26]  E. Junn,et al.  MicroRNAs in neurodegenerative diseases and their therapeutic potential. , 2012, Pharmacology & therapeutics.

[27]  R H Myers,et al.  Decreased Neuronal and Increased Oligodendroglial Densities in Huntington's Disease Caudate Nucleus , 1991, Journal of neuropathology and experimental neurology.

[28]  Xavier Estivill,et al.  A myriad of miRNA variants in control and Huntington’s disease brain regions detected by massively parallel sequencing , 2010, Nucleic acids research.

[29]  Thomas Ragg,et al.  The RIN: an RNA integrity number for assigning integrity values to RNA measurements , 2006, BMC Molecular Biology.

[30]  B Fischl,et al.  Regional cortical thinning in preclinical Huntington disease and its relationship to cognition , 2005, Neurology.

[31]  R. Shiekhattar,et al.  Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies , 2008, Proceedings of the National Academy of Sciences.

[32]  M. Sinha,et al.  Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP. , 2010, Biochemical and biophysical research communications.

[33]  B. Swalla.  Building divergent body plans with similar genetic pathways , 2006, Heredity.

[34]  D. Raveh,et al.  Sequestration of Highly Expressed mRNAs in Cytoplasmic Granules, P-Bodies, and Stress Granules Enhances Cell Viability , 2012, PLoS genetics.

[35]  Emmette R. Hutchison,et al.  Interrogation of brain miRNA and mRNA expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin , 2012, Journal of neurochemistry.

[36]  J. Cha,et al.  Transcriptional signatures in Huntington's disease , 2007, Progress in Neurobiology.

[37]  C. Ross,et al.  Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation , 2003, Neuroreport.

[38]  Paul J. Hertzog,et al.  Analysis of microRNA turnover in mammalian cells following Dicer1 ablation , 2011, Nucleic acids research.

[39]  D. Rubinsztein,et al.  Decreased cAMP Response Element-mediated Transcription , 2004, Journal of Biological Chemistry.

[40]  K. Storey,et al.  Opposing FGF and retinoid pathways: a signalling switch that controls differentiation and patterning onset in the extending vertebrate body axis , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[41]  J. Olson,et al.  Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.

[42]  H. Horvitz,et al.  MicroRNA Expression in Zebrafish Embryonic Development , 2005, Science.

[43]  W. Filipowicz,et al.  Relief of microRNA-Mediated Translational Repression in Human Cells Subjected to Stress , 2006, Cell.

[44]  Daniel Chourrout,et al.  Genome Regulation by Polycomb and Trithorax Proteins , 2007, Cell.

[45]  T. Svingen,et al.  Hox transcription factors and their elusive mammalian gene targets , 2006, Heredity.

[46]  L. Greene,et al.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[47]  R. Parker,et al.  Polysomes, P bodies and stress granules: states and fates of eukaryotic mRNAs. , 2009, Current opinion in cell biology.

[48]  A. Durston,et al.  MiR-10 Represses HoxB1a and HoxB3a in Zebrafish , 2008, PloS one.

[49]  R. Stallings,et al.  MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2 , 2011, Cell Death and Differentiation.

[50]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[51]  J L Haines,et al.  Supporting Online Material Materials and Methods Figs. S1 to S7 Tables S1 to S4 References Mutations in the Fus/tls Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis , 2022 .

[52]  R. S. Williams,et al.  Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington's disease , 1993, Neurology.

[53]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[54]  G. Sobue,et al.  Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2 , 2012, Nature Medicine.

[55]  A. Lund,et al.  The miR-10 microRNA precursor family , 2011, RNA biology.

[56]  S. Tabrizi,et al.  Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. , 2011, Human molecular genetics.

[57]  B. Wolozin.  Regulated protein aggregation: stress granules and neurodegeneration , 2012, Molecular Neurodegeneration.

[58]  D. Bartel,et al.  MicroRNAs in the Hox network: an apparent link to posterior prevalence , 2008, Nature Reviews Genetics.

[59]  Xun Hu,et al.  TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis , 2008, Science.

[60]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[61]  Howard Y. Chang,et al.  Functional Demarcation of Active and Silent Chromatin Domains in Human HOX Loci by Noncoding RNAs , 2007, Cell.

[62]  William McGinnis,et al.  Genomic Evolution of Hox Gene Clusters , 2006, Science.

[63]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[64]  Richard H. Myers,et al.  Assessment of cortical and striatal involvement in 523 Huntington disease brains , 2012, Neurology.

[65]  Raquel P. Ritchie,et al.  miR-10a Contributes to Retinoid Acid-induced Smooth Muscle Cell Differentiation* , 2010, The Journal of Biological Chemistry.

[66]  W. Filipowicz,et al.  Dendrites of Mammalian Neurons Contain Specialized P-Body-Like Structures That Respond to Neuronal Activation , 2008, The Journal of Neuroscience.

[67]  J. Belasco,et al.  A Role for Huntington Disease Protein in Dendritic RNA Granules* , 2010, The Journal of Biological Chemistry.

[68]  Joseph C. Pearson,et al.  Modulating Hox gene functions during animal body patterning , 2005, Nature Reviews Genetics.

[69]  H. Taylor,et al.  HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium. , 1998, The Journal of clinical investigation.

[70]  M. MacDonald,et al.  Huntingtin facilitates polycomb repressive complex 2 , 2009, Human molecular genetics.

[71]  E. Siemers,et al.  Subtle changes among presymptomatic carriers of the Huntington's disease gene , 2000, Journal of neurology, neurosurgery, and psychiatry.

[72]  Yi Xing,et al.  The Bifunctional microRNA miR-9/miR-9* Regulates REST and CoREST and Is Downregulated in Huntington's Disease , 2008, The Journal of Neuroscience.

[73]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[74]  G. Hong,et al.  Nucleic Acids Research , 2015, Nucleic Acids Research.

[75]  M. Cudkowicz,et al.  Degeneration of pyramidal projection neurons in Huntington's disease cortex , 1990, Annals of neurology.

[76]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[77]  He Li,et al.  Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments. , 2010, Human molecular genetics.

[78]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.